Emerging anxiolytics

Expert Opin Emerg Drugs. 2007 Nov;12(4):541-54. doi: 10.1517/14728214.12.4.541.

Abstract

Anxiety disorders are the most common of the psychiatric disorders and are also associated with significant economic costs and impaired work productivity. The first-line pharmacotherapy of pharmatherapy for a number of anxiety disorders comprises selective serotonin re-uptake inhibitors (SSRIs) and serotonin and noradrenaline re-uptake inhibitors (SNRIs). Benzodiazepines are still widely used for the treatment of several anxiety disorders. Although these agents are effective, many patients are treatment-refractory and more effective, better tolerated medications are required. This paper discusses the understandings of mechanisms involved in the anxiety disorders and reviews emerging medications. Mechanisms underlying the use of d-cycloserine, second generation antipsychotics and beta-blockers are particularly exciting.

Publication types

  • Review

MeSH terms

  • Anti-Anxiety Agents* / chemistry
  • Anti-Anxiety Agents* / pharmacology
  • Anti-Anxiety Agents* / therapeutic use
  • Antidepressive Agents / chemistry
  • Antidepressive Agents / pharmacology
  • Antidepressive Agents / therapeutic use
  • Antipsychotic Agents / chemistry
  • Antipsychotic Agents / pharmacology
  • Antipsychotic Agents / therapeutic use
  • Anxiety Disorders* / drug therapy
  • Anxiety Disorders* / metabolism
  • Anxiety Disorders* / psychology
  • Clinical Trials as Topic
  • Drug Design*
  • Humans
  • Molecular Structure
  • Serotonin Uptake Inhibitors / chemistry
  • Serotonin Uptake Inhibitors / pharmacology
  • Serotonin Uptake Inhibitors / therapeutic use

Substances

  • Anti-Anxiety Agents
  • Antidepressive Agents
  • Antipsychotic Agents
  • Serotonin Uptake Inhibitors